Study familial hypertrophic cardiomyopathy using patient-specific induced pluripotent stem cells

Aims Familial hypertrophic cardiomyopathy (HCM) is one the most common heart disorders, with gene mutations in the cardiac sarcomere. Studying HCM with patient-specific induced pluripotent stem-cell (iPSC)-derived cardiomyocytes (CMs) would benefit the understanding of HCM mechanism, as well as the development of personalized therapeutic strategies. Methods and results To investigate themolecularmechanismunderlying the abnormalCM functions inHCM,we derived iPSCs fromanHCM patientwith a singlemissensemutation (Arginine442Glycine) in theMYH7gene.CMswerenext enriched fromHCMand healthy iPSCs, followedwithwhole transcriptomesequencingandpathwayenrichment analysis.Awidespread increaseof genes responsible for ‘Cell Proliferation’was observed inHCM iPSC-CMswhen comparedwith control iPSC-CMs. Add